🚀 VC round data is live in beta, check it out!
Blau Farmacêutica Valuation Multiples
Discover revenue and EBITDA valuation multiples for Blau Farmacêutica and similar public comparables like Invivyd, Solid Biosciences, Eupraxia Pharmaceuticals, Vanda Pharmaceuticals and more.
Blau Farmacêutica Overview
About Blau Farmacêutica
Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company’s business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital’s daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.
Founded
1987
HQ
Employees
2.1K
Website
Sectors
Financials (LTM)
EV
$461M
Blau Farmacêutica Financials
Blau Farmacêutica reported last 12-month revenue of $340M and EBITDA of $87M.
In the same LTM period, Blau Farmacêutica generated $87M in EBITDA and $54M in net income.
Revenue (LTM)
Blau Farmacêutica P&L
In the most recent fiscal year, Blau Farmacêutica reported revenue of $333M and EBITDA of $76M.
Blau Farmacêutica expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $340M | XXX | $333M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $125M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 38% | XXX | XXX | XXX |
| EBITDA | $87M | XXX | $76M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $54M | XXX | $41M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | — | — | $92M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Blau Farmacêutica Stock Performance
Blau Farmacêutica has current market cap of $478M, and enterprise value of $461M.
Market Cap Evolution
Blau Farmacêutica's stock price is $2.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $461M | $478M | -1.3% | XXX | XXX | XXX | $0.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBlau Farmacêutica Valuation Multiples
Blau Farmacêutica trades at 1.4x EV/Revenue multiple, and 5.3x EV/EBITDA.
EV / Revenue (LTM)
Blau Farmacêutica Financial Valuation Multiples
As of March 21, 2026, Blau Farmacêutica has market cap of $478M and EV of $461M.
Equity research analysts estimate Blau Farmacêutica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Blau Farmacêutica has a P/E ratio of 8.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $478M | XXX | $478M | XXX | XXX | XXX |
| EV (current) | $461M | XXX | $461M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.3x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBIT | 6.2x | XXX | 7.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.7x | XXX | XXX | XXX |
| P/E | 8.8x | XXX | 11.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 6.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Blau Farmacêutica Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Blau Farmacêutica Margins & Growth Rates
Blau Farmacêutica's revenue in the last 12 month grew by 14%.
Blau Farmacêutica's revenue per employee in the last FY averaged $0.2M.
Blau Farmacêutica's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Blau Farmacêutica's rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Blau Farmacêutica Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 18% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Blau Farmacêutica Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Invivyd | XXX | XXX | XXX | XXX | XXX | XXX |
| Solid Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Eupraxia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Vanda Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Emergent BioSolutions | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Blau Farmacêutica M&A Activity
Blau Farmacêutica acquired XXX companies to date.
Last acquisition by Blau Farmacêutica was on XXXXXXXX, XXXXX. Blau Farmacêutica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Blau Farmacêutica
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBlau Farmacêutica Investment Activity
Blau Farmacêutica invested in XXX companies to date.
Blau Farmacêutica made its latest investment on XXXXXXXX, XXXXX. Blau Farmacêutica invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Blau Farmacêutica
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Blau Farmacêutica
| When was Blau Farmacêutica founded? | Blau Farmacêutica was founded in 1987. |
| Where is Blau Farmacêutica headquartered? | Blau Farmacêutica is headquartered in Brazil. |
| How many employees does Blau Farmacêutica have? | As of today, Blau Farmacêutica has over 2K employees. |
| Who is the CEO of Blau Farmacêutica? | Blau Farmacêutica's CEO is Marcelo Rodolfo Hahn. |
| Is Blau Farmacêutica publicly listed? | Yes, Blau Farmacêutica is a public company listed on B3. |
| What is the stock symbol of Blau Farmacêutica? | Blau Farmacêutica trades under BLAU3 ticker. |
| When did Blau Farmacêutica go public? | Blau Farmacêutica went public in 2021. |
| Who are competitors of Blau Farmacêutica? | Blau Farmacêutica main competitors are Invivyd, Solid Biosciences, Eupraxia Pharmaceuticals, Vanda Pharmaceuticals. |
| What is the current market cap of Blau Farmacêutica? | Blau Farmacêutica's current market cap is $478M. |
| What is the current revenue of Blau Farmacêutica? | Blau Farmacêutica's last 12 months revenue is $340M. |
| What is the current revenue growth of Blau Farmacêutica? | Blau Farmacêutica revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Blau Farmacêutica? | Current revenue multiple of Blau Farmacêutica is 1.4x. |
| Is Blau Farmacêutica profitable? | Yes, Blau Farmacêutica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Blau Farmacêutica? | Blau Farmacêutica's last 12 months EBITDA is $87M. |
| What is Blau Farmacêutica's EBITDA margin? | Blau Farmacêutica's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Blau Farmacêutica? | Current EBITDA multiple of Blau Farmacêutica is 5.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.